News brief
On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年7月2日，据烯牛数据报道，睿健医药完成C+融资，金额2.60亿人民币。投资方为成都科创投领投，中信建投资本、锡创投、鼎泰星、新基业、弘毅资本、元希海河（天津）生物医药产业基金合伙企业（有限合伙）跟投。该公司为化学诱导细胞治疗药物研发商。